The effects of flurazepam, lorazepam, and triazolam on sleep and memory.

Texas Medical Center
Psychopharmacology (Impact Factor: 3.99). 02/1980; 70(3):231-7. DOI: 10.1007/BF00427879
Source: PubMed

ABSTRACT This study evaluated the effects of flurazepam 30 mg, lorazepam 4 mg, triazolam 0.5 mg, and placebo upon sleep and memory in eleven normal male subjects continuously monitored for nighttime EEG, EOG, and EMG recording. Subjects received each drug or placebo for two consecutive nights per week for 4 weeks in a repeated measures, double-blind, Latin Square design. Three hours post-administration, subjects were awakened and presented with a series of tasks. Recall was assessed immediately following task presentation and after the final morning awakening. The results showed that every drug significantly decreased stage 1, increased stage 2, and produced no change in stage 3--4 sleep in comparison to placebo. Only lorazepam significantly decreased REM percent. Post-drug recall was significantly decreased in comparison to placebo at night and was further decreased in the morning. Morning recall was significantly poorer when the return to sleep was 2.5 min or less than when the return to sleep was greater than 5 min following the nighttime awakening in all drug conditions. These results indicate that 1. failure of memory consolidation rather than failure of retrieval is the most likely explanation for the morning memory loss and 2. hypnotic drug properties, measured by latency to fall back asleep, affect memory consolidation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In this open‐label study using final evaluator blinding, the efficacy of yokukansan (YKS) was evaluated in six psychophysiological insomnia patients using the cyclic alternating pattern (CAP) method. YKS had no influence on objective sleep parameters by the Rechtschaffen & Kales method, but the CAP rate and CAP cycle frequency decreased significantly. In the subjective Visual Analog Scale test, significant improvement was seen in five items: tension, calmness, fatigue, heavy‐headedness and lassitude. No adverse reactions were noted. YKS improved sleep quality without influencing sleep structure and showed no adverse reactions, suggesting that YKS is an effective anti‐insomnia drug with good tolerability.
    Sleep and Biological Rhythms 04/2012; 10(2). DOI:10.1111/j.1479-8425.2011.00527.x · 0.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: UDC 612.825.5:612.833 The discovery of benzodiazepine receptors in the brain and the important role postulated for the benzodiazepine system of the brain, including an as yet unidentified endogenous figand, in the regulation of its functional activity makes the study of the role of this system in learning and memory a problem for urgent consideration. The urgency of this problem is also determined by the fact that among the many pharmacological effects of benzodiazepine tranquilizers [i-3], memory disturbances of the anterograde amnesia type have been described [5, 7, 8, ii, 14-16]. The ability of benzodiazepine receptors of synaptic membranes to bind exogenous benzodiazepines, can serve as a parameter of the functional state of the benzodiazepine system of the brain, for it varies under the influence of functional loads [6, 12]. It has been suggested that changes in binding of exogenous benzodiazepines by synaptic membranes are due to changes in the number and affinity of the receptors [6] and competition between the endogenous ligand secreted during appropriate functional loads with exogenous benzodiazepines for the receptor [12]. The effect of conditioning on binding of 3H-diazepam ~n v~t~o by synaptic membranes isolated from the cerebral cortex was investigated. EXPERIMENTAL METHOD Noninbred male albino rats weighing 130-150 g were used. Two-way defensive conditioned avoidance reflexes were formed in a shuttle box. The conditioned stimuli were flashes at the 6th second of action of which an electric shock was applied to the animals through the floor. Conditioning was continued until five out of six correct responses were obtained. Animals receiving the same number of photic and electrodermal stimulations as the corresponding experimental animals, but not as combinations, served as the active control (AC). Animals not exposed to any specific procedures served as the passive control. Each group consisted of 5-7 rats. The animals were decapitated immediately after the experiments, the brain removed, and the separated cortex was placed in liquid nitrogen. After thawing, the tissue was homogenized in a Potter's homogenizer in 25 volumes of Tris-HCl buffer solution consisting of 0.32M sucrose, O.001 EDTA, and 0.05M Tris-HCl, pH 7.4, at 4~ The suspension thus obtained was centrifuged for 15 min at 200g, the residue was discarded, and the supernatant was centrifuged for 20 min at 20,000g. The residue thus obtained (R2) was suspended in 25 volumes (of the initial tissue) of 0.05M Tris-HCl solution (pH 7.4) and the suspension was frozen at --20~ for keeping not more than i0 days. Binding of 3H-diazepam (specific activity 87 Ci/mmole, Amersham, England) with synaptic membranes of R2 was carried out in a total volume of 0.5 ml. The reaction mixture consisted of 50 ~i of a solution of 3H-diazepam of appropriate concentration (from 0.37 to 70 nM), 50 ~l water or 2"10 -4 M diazepam (to determine nonspecific binding). The reaction was started by addition of 400 ~i of membrane suspension from R2. Incubation continued for 30 min at 0.5-I~ The mixture was treated with 4 ml of 0.05M Tris-HCl buffer, pH 7.4, and the suspension was filtered on a water-jet pump through GF/B filters (from Whatman, England), which were then washed twice with 4 ml of the same buffer. After drying overnight, the radioactivity of the filters was Laboratory of Neurochemical Mechanisms of Conditioned Reflexes, Institute of Higher Nervous Activity and Neurophysiology, Academy of Sciences of the USSR, Moscow. (Presented by Academician of the Academy of Medical Sciences of the USSR V. S. Rusinov.) Translated from Byulleten' Eksperimental'noi
    Bulletin of Experimental Biology and Medicine 12/1981; 92(6):1668-1670. DOI:10.1007/BF00837705 · 0.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: Lorazepam, a benzodiazepine anxiolytic, may increase daytime sleepiness and impair psychomotor performance, which is hazardous for patients engaging in daily activities such as car driving. Given current prescription practice, information on the repeated dose effects is required. The 5-HT2A/2C antagonist ritanserin was originally developed as a safer alternative to the benzodiazepines, yet having limited clinical efficacy. 5HT2A/2C receptors have been implicated in regulating slow-wave sleep but little is known about their role in human performance. Objective: The present study investigated the subchronic effects of the benzodiazepine anxiolytic lorazepam and the 5-HT2A/2C antagonist ritanserin on actual driving performance, objective and subjective sleepiness, and nocturnal slow wave sleep. Methods: Eighteen healthy volunteers were treated twice daily for 7 days with ritanserin 5 mg, lorazepam 1.5 mg or placebo. Treatments were administered according to a double-blind, cross-over design. Tests were performed on day 7 of each treatment week. Sleep EEG was recorded during the preceding night. Results: Lorazepam had a pronounced impairing effect on lateral position control and induced daytime sleepiness, while having no effect on other parameters. In contrast, ritanserin did not impair driving performance or affect objectively measured daytime sleepiness, while subjects reported to feel more alert during daytime. Moreover, consistent with its effects on 5-HT2 receptors, ritanserin increased the amount of nocturnal slow wave sleep. There were no relationships between changes in slow wave sleep and performance parameters. Conclusions: Lorazepam administered for 7 consecutive days may be hazardous for patients who engage in driving activities. Antagonism of 5-HT2A/2C receptors, as accomplished by ritanserin, increases slow wave sleep and is devoid of effects on objective sleepiness and driving behaviour. Whether this extends to other cognitive and psychomotor domains remains to be established.
    Psychopharmacology 03/2001; 154(2):189-197. DOI:10.1007/s002130000633 · 3.99 Impact Factor